Loading clinical trials...
Loading clinical trials...
PART 1: 1. To explore the safety of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma. 2. To determine the recommended Phase II dosing regimen for relapsed or ref...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT06395103 · B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, and more
NCT04728893 · Hematologic Malignancies, Waldenstroms Macroglobulinaemia, and more
NCT05100862 · Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
NCT06678659 · Unresectable, Locally Advanced, and more
NCT06191744 · Follicular Lymphoma (FL)
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions